4 Midcap Earnings Per Share Between Rs 25 and 100 Stocks to Watch for Future Multibagger Potential: MCX, SRF, Radico Khaitan and Ajanta Pharma
- October 30, 2026
- Posted by: Manan Bisht
- Category: Best Stocks
MCX Rs 3,231. SRF Rs 2,358.60. Radico Khaitan Rs 4,235. Ajanta Pharma Rs 3,459.70. Market caps from Rs 43,549 crore to Rs 83,658 crore. Data as of 29 Oct 2026.
Quick Answer
MCX, SRF, Radico Khaitan and Ajanta Pharma are the 4 picks in this earnings per share between Rs 25 and 100 stocks watchlist, with market caps between Rs 43,549 crore and Rs 83,658 crore. MCX stands out for the highest return on equity at 46.75%, while SRF offers the lowest PE of the group at 34.61. PE ratios run from 34.61 to 84.61, so compare each one with its industry PE before investing. All figures are as of 29 October 2026.
Earnings per share between Rs 25 and 100 stocks to watch for multibagger potential start with a simple filter: size, a clean financial record and earnings that keep growing. MCX, SRF, Radico Khaitan and Ajanta Pharma meet that test, with market caps from Rs 43,549 crore to Rs 83,658 crore and MCX offering the highest return on equity at 46.75%. Each of these companies has a market capitalisation between Rs 30,000 crore and Rs 1,00,000 crore and an earnings per share between Rs 25 and Rs 100, worked out as the share price divided by the price to earnings ratio, a return on equity of at least 10 per cent and profit growth in FY26 and in the latest quarter, and net profit rose in FY26 and in the latest quarter.
This list covers companies with a market capitalisation between Rs 30,000 crore and Rs 1,00,000 crore and an earnings per share between Rs 25 and Rs 100, worked out as the share price divided by the price to earnings ratio, a return on equity of at least 10 per cent and profit growth in FY26 and in the latest quarter, rising profit in FY26 and the latest quarter, and complete, verifiable financials, ranked by market capitalisation. Each company has a market cap between Rs 30,000 crore and Rs 1 lakh crore. Investors screening earnings per share between Rs 25 and 100 stocks usually begin with size and balance sheet strength, and this list follows the same logic. All figures are as of 29 October 2026 and are drawn from NSE and BSE data and company filings.
Click Here – Get Free Investment Predictions
What Are Earnings Per Share Between Rs 25 and 100 Stocks and Why Do They Attract Multibagger Interest?
Earnings per share between Rs 25 and 100 stocks are shares of mid sized companies that earn between Rs 25 and Rs 100 of profit on every share, a healthy middle band that combines solid earning power with room for the share price to grow. The four here cover commodity exchange services, specialty chemicals, spirits and pharmaceuticals.
An earnings per share in this band shows that the company earns well on each share without carrying a very high price tag, and rising profit pushes that figure higher each year. Within earnings per share between Rs 25 and 100 stocks, the four companies show rising profit. In earnings per share between Rs 25 and 100 stocks, each of the four also posted growth in the latest quarter. For earnings per share between Rs 25 and 100 stocks, both FY26 and the latest quarter showed growth. Whichever way you read earnings per share between Rs 25 and 100 stocks, the common thread is rising profit backed by complete financial data. With earnings per share between Rs 25 and 100 stocks, comparing valuation, growth and balance sheet strength together works better than relying on one number. Every company in the table below passed a rising-profit check, and the figures for earnings per share between Rs 25 and 100 stocks are complete. Read each company’s latest results and exchange filings before acting on earnings per share between Rs 25 and 100 stocks.
Earnings Per Share Between Rs 25 and 100 Stocks at a Glance: Price, Market Cap, PE and ROE
Prices are closing prices as of 29 October 2026. SRF has the lowest PE of the group at 34.61, while MCX posts the highest return on equity at 46.75%.
| Stock | CMP (Rs) | Market Cap (Rs Cr) | PE | Industry PE | ROE | Debt to Equity | 52-Week Range (Rs) |
|---|---|---|---|---|---|---|---|
| Multi Commodity Exchange of India | 3,231 | 83,658 | 54.26 | 42.17 | 46.75% | 0.00 | 1,762.10 to 3,481.40 |
| SRF | 2,358.60 | 74,824 | 34.61 | 36.15 | 13.07% | 0.36 | 2,310.00 to 3,210.00 |
| Radico Khaitan | 4,235 | 59,531 | 84.61 | 54.95 | 18.23% | 0.15 | 2,500.00 to 4,747.00 |
| Ajanta Pharma | 3,459.70 | 43,549 | 38.37 | 36.35 | 23.33% | 0.06 | 2,380.20 to 3,796.00 |
MCX: 74.55% Profit CAGR Since FY22
MCX is India’s leading commodity derivatives exchange, where gold, silver, crude oil, natural gas and base metals contracts are traded. It reported FY26 revenue of Rs 2,429.05 crore, up 100.94% year on year, and net profit of Rs 1,331.55 crore, up 137.76%. Net profit has compounded at 74.55% a year since FY22, while revenue has grown 53.87% a year. Operating margin was 76.83% in FY26. The debt-to-equity ratio is 0.00, which keeps interest costs low.
In the June 2026 quarter, revenue rose 85.25% to Rs 751.79 crore and net profit grew 103.47% to Rs 413.44 crore. The share price has gained 720.06% over five years and 69.44% over the past year. Foreign investors raised their holding from 21.69% in June 2025 to 29.84% in June 2026. The stock trades at a PE of 54.26 against an industry PE of 42.17, with a return on equity of 46.75%.
SRF: Quarterly Profit Up 75.53%
SRF operates in specialty chemicals, packaging films and technical textiles, and its chemicals business is a key earnings driver. It reported FY26 revenue of Rs 15,893.57 crore, up 7.20% year on year, and net profit of Rs 1,835.18 crore, up 46.72%. Revenue has compounded at 6.08% a year since FY22. Operating margin was 21.74% in FY26. The debt-to-equity ratio is 0.36.
The stock trades at a PE of 34.61 against an industry PE of 36.15, below the sector average, with a return on equity of 13.07%. In the June 2026 quarter, revenue rose 31.69% to Rs 5,067.17 crore and net profit grew 75.53% to Rs 758.87 crore. Domestic institutions raised their holding from 18.85% in June 2025 to 22.44% in June 2026.
Radico Khaitan: 24.88% Profit CAGR Since FY22
Radico Khaitan makes Indian-made foreign liquor and premium spirits, with brands including Magic Moments, 8PM and Rampur Single Malt. It reported FY26 revenue of Rs 6,062.27 crore, up 24.84% year on year, and net profit of Rs 604.48 crore, up 74.90%. Net profit has compounded at 24.88% a year since FY22, while revenue has grown 20.50% a year. Operating margin was 4.88% in FY26. The debt-to-equity ratio is 0.15, which keeps interest costs low.
In the June 2026 quarter, revenue rose 10.44% to Rs 5,869.46 crore and net profit grew 75.91% to Rs 229.60 crore. The share price has gained 299.58% over five years and 51.47% over the past year. Domestic institutions raised their holding from 25.47% in September 2025 to 27.17% in September 2026. The stock trades at a PE of 84.61 against an industry PE of 54.95, with a return on equity of 18.23%.
Ajanta Pharma: Return on Equity of 23.33%
Ajanta Pharma sells branded generics in ophthalmology, dermatology, cardiology and pain management in India, Africa and Asia. It reported FY26 revenue of Rs 5,624.93 crore, up 18.60% year on year, and net profit of Rs 1,056 crore, up 14.73%. Net profit has compounded at 10.33% a year since FY22, while revenue has grown 12.94% a year. Operating margin was 28.74% in FY26. The debt-to-equity ratio is 0.06, which keeps interest costs low.
The stock trades at a PE of 38.37 against an industry PE of 36.35, with a return on equity of 23.33%. In the June 2026 quarter, revenue rose 27.68% to Rs 1,696.86 crore and net profit grew 30.89% to Rs 334.22 crore. The share price has gained 125.31% over five years and 35.42% over the past year. Domestic institutions raised their holding from 17.90% in September 2025 to 21.94% in September 2026.
Earnings Per Share Between Rs 25 and 100 Stocks: Financial Comparison on Growth and Margins
The table compares scale and growth across these earnings per share between Rs 25 and 100 stocks. Latest quarter means the most recent reported quarter for each company, and only metrics that are positive for every company are shown.
| Stock | Revenue (Rs Cr) | Net Profit (Rs Cr) | Revenue Growth (YoY) | 4-Year Revenue CAGR | Latest Quarter Revenue Growth | Operating Margin (Latest Quarter) |
|---|---|---|---|---|---|---|
| MCX | 2,429.05 | 1,331.55 | 100.94% | 53.87% | 85.25% | 77.49% |
| SRF | 15,893.57 | 1,835.18 | 7.20% | 6.08% | 31.69% | 25.73% |
| Radico Khaitan | 6,062.27 | 604.48 | 24.84% | 20.50% | 10.44% | 6.10% |
| Ajanta Pharma | 5,624.93 | 1,056 | 18.60% | 12.94% | 27.68% | 30.41% |
Check the Univest Screener for live data on these earnings per share between Rs 25 and 100 stocks
Institutional Holding in MCX, SRF, Radico Khaitan and Ajanta Pharma
Institutional holding shows who is backing these earnings per share between Rs 25 and 100 stocks alongside the promoter. The table uses the latest reported quarter for each. MCX has the deepest institutional backing, with FII and DII together holding 80.65% as of June 2026. Domestic institutions increased their holding over the past year in SRF (from 18.85% to 22.44%), Radico Khaitan (from 25.47% to 27.17%) and Ajanta Pharma (from 17.90% to 21.94%).
| Stock | Promoter | FII | DII | Public | Quarter |
|---|---|---|---|---|---|
| MCX | Nil | 29.84% | 50.81% | 19.34% | June 2026 |
| SRF | 50.26% | 15.45% | 22.44% | 11.85% | June 2026 |
| Radico Khaitan | 40.17% | 19.43% | 27.17% | 13.23% | September 2026 |
| Ajanta Pharma | 63.47% | 7.63% | 21.94% | 6.96% | September 2026 |
Risks to Weigh in Earnings Per Share Between Rs 25 and 100 Stocks
Being careful with earnings per share between Rs 25 and 100 stocks means looking at what can slow the story as well as what can speed it up. Four points matter most:
- Past growth may not repeat.
- Share prices can move sharply in either direction.
- Valuation: Radico Khaitan trades at a PE of 84.61 against an industry PE of 54.95, so earnings need to keep growing to support the price.
- Concentration: Holding all 4 names puts the allocation in one sector, so size each position to match your risk appetite.
How to Choose Between Earnings Per Share Between Rs 25 and 100 Stocks
Picking from earnings per share between Rs 25 and 100 stocks comes down to four checks, applied in order.
- Check balance sheet strength first, and prefer a debt-to-equity ratio below 1 for non-financial companies.
- Compare each PE with the industry PE (36.15 to 54.95) and ask whether the growth rate justifies any gap.
- Track net profit growth, the operating margin and the return on equity in every quarterly result.
- Stagger entries across quarters and review institutional holding every reporting season.
Download the Univest iOS App or Univest Android App to track MCX, SRF, Radico Khaitan and Ajanta Pharma live prices.
Conclusion
Among earnings per share between Rs 25 and 100 stocks, MCX stands out for the highest return on equity at 46.75%, SRF for the lowest PE of the group at 34.61, Radico Khaitan for 24.84% revenue growth in FY26 and Ajanta Pharma for a nearly debt-free balance sheet, with a debt-to-equity ratio of 0.06. Which one suits a portfolio depends on how much valuation risk it can carry, so staggering entries and reviewing each quarterly result is a sound habit. Investors comparing earnings per share between Rs 25 and 100 stocks should rank them on growth, financial strength and the price paid, and anyone who wants personalised guidance can consult a SEBI-registered advisor before acting.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions on Earnings Per Share Between Rs 25 and 100 Stocks to Watch
Which are the best earnings per share between Rs 25 and 100 stocks to watch for multibagger potential?
Ans. MCX, SRF, Radico Khaitan and Ajanta Pharma are the 4 names this list highlights, with market caps of Rs 83,658 crore, Rs 74,824 crore, Rs 59,531 crore and Rs 43,549 crore respectively. MCX is notable for the highest return on equity at 46.75%. SRF stands out for the lowest PE of the group at 34.61. Radico Khaitan offers 24.84% revenue growth in FY26. Ajanta Pharma brings a nearly debt-free balance sheet, with a debt-to-equity ratio of 0.06. These are watchlist names for earnings per share between Rs 25 and 100 stocks, not recommendations, so match each one to your own risk profile and time horizon.
Is MCX a good stock for long-term investors?
Ans. MCX has a return on equity of 46.75%, a PE of 54.26 against an industry PE of 42.17 and a market cap of Rs 83,658 crore. Net profit has compounded at 74.55% a year since FY22, and FY26 revenue rose 100.94% while June 2026 quarter net profit grew 103.47%. Long-term returns in earnings per share between Rs 25 and 100 stocks depend on earnings growth and the price paid at entry, so staggering purchases and consulting a SEBI-registered advisor is sensible.
Can Radico Khaitan become a multibagger from here?
Ans. Radico Khaitan has already gained 299.58% in five years, so another multi-fold move would need sustained earnings growth. A multibagger outcome in earnings per share between Rs 25 and 100 stocks requires earnings to keep growing faster than the market for several years. Net profit has compounded at 24.88% a year since FY22, and FY26 revenue rose 24.84%. At a PE of 84.61 against an industry PE of 54.95, valuation should be checked against that growth before investing.
What is the market cap of MCX, SRF, Radico Khaitan and Ajanta Pharma?
Ans. As of 29 October 2026, MCX has a market cap of Rs 83,658 crore, SRF has a market cap of Rs 74,824 crore, Radico Khaitan has a market cap of Rs 59,531 crore and Ajanta Pharma has a market cap of Rs 43,549 crore. All of them qualify as midcaps. Market cap changes daily with the share price, so check the latest figure on the Univest Screener or on NSE before taking a decision on earnings per share between Rs 25 and 100 stocks.
What are the risks of investing in earnings per share between Rs 25 and 100 stocks?
Ans. The main risks are market swings, slower growth than expected and valuations that already reflect good news. Companies with strong balance sheets and steady earnings handle these better. Radico Khaitan trades at a PE of 84.61 against an industry PE of 54.95, so earnings growth needs to hold up.
Why is Radico Khaitan trading at a PE of 84.61?
Ans. Radico Khaitan’s PE of 84.61 compares with an industry PE of 54.95. The market is paying a premium for a return on equity of 18.23%, profit growth of 24.88% a year since FY22 and latest-quarter profit growth of 75.91%, which also means the stock is more sensitive if growth slows. Investors in earnings per share between Rs 25 and 100 stocks who are comfortable with higher valuation risk may prefer to stagger purchases instead of investing in one go.
How much do institutions hold in MCX, SRF, Radico Khaitan and Ajanta Pharma?
Ans. As of the latest reported quarter, FII and DII together hold 80.65% of MCX (29.84% and 50.81%), 37.89% of SRF (15.45% and 22.44%), 46.60% of Radico Khaitan (19.43% and 27.17%) and 29.57% of Ajanta Pharma (7.63% and 21.94%). Rising institutional holding is a useful signal in earnings per share between Rs 25 and 100 stocks, though it should be read with earnings trends rather than on its own.
